Sanwa licenses DPP-4 inhibitor to Choongwae
This article was originally published in Scrip
Sanwa Kagaku Kenkyusho has licensed its pipeline DPP-4 inhibitor antidiabetic SK-0403 to Choongwae Pharma for development and commercialisation in South Korea. The Japanese firm, which is part of the Japanese pharmaceutical wholesaling group Suzuken, will receive undisclosed up-front, milestone and sales-based royalties as part of the deal. SK-0403 is currently in Phase II development in Japan, where it has just been licensed to Kowa for joint development and commercialisation.
You may also be interested in...
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.